نتائج البحث - "Tryakin, A."

العلاقة: https://www.malignanttumors.org/jour/article/view/1273/911Test; Al-Batran SE, Homann N, Pauligk C. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4) : a randomised, phase 2 / 3 trial. Lancet. 2019 May 11; 393 (10179) : 1948–1957. doi:10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11. PMID: 30982686.; Al-Batran SE, Hofheinz RD, Pauligk C et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO) : results from the phase 2 part of a multicentre, open-label, randomised phase 2 / 3 trial. Lancet Oncol. 2016 Dec; 17 (12) : 1697–1708. doi:10.1016/S1470-2045(16)30531-9. Epub 2016 Oct 22. PMID: 27776843.; Stark AP, Ikoma N, Chiang YJ et al. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol. 2019 Oct; 26 (11) : 3602–3610. doi:10.1245/s10434-019-07638-8. Epub 2019 Jul 26. PMID: 31350645.; Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994; 73 : 2680–6.; Lauren P. The two histological main types of gastric carcinoma : diff use and so-called intestinal-type carcinoma. An attempt at a histo-clinical classifi cation. Acta Pathol Microbiol Scand 1965; 64 : 31–49.; Dindo D, Demartines N, Clavien PA. Classification of surgical complications : a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240 (2) : 205–213.; Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M. et al. Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136 : E359–86).; Cunningham D, Allum WH, Stenning SP, Thompson JN, et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355 : 11–20.; Ychou,M, Boige, V, Pignon,J-P, Conroy T,et al. Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma : An FNCLCC and FFCD Multicenter Phase III Trial. J Clin Oncol 29 : 1715–1721).; Трусилова, Е. Эффективность и токсичность химиотерапии по схеме FOLFIRINOX у больных диссеминированным раком желудка. Предварительные результаты / Е.В. Трусилова, Н.С. Бесова, В.А. Горбунова и др. // Эффективная фармакотерапия. Онкология, гематология, радиология .– 2013 .– Т. 46 (4) .– С. 6–13.; International Union Against Cancer (UICC). TNM Classification of Malignant Tumours, 7th ed. Sobin L.H., Gospodarowicz M.K., Wittekind Ch., eds. New York : Wiley-Blackwell; 2009.; https://www.malignanttumors.org/jour/article/view/1273Test

الإتاحة: https://doi.org/10.18027/2224-5057-2023-13-4-7-17Test
https://doi.org/10.1016/S0140-6736Test(18)32557-1
https://doi.org/10.1016/S1470-2045Test(16)30531-9
https://doi.org/10.1245/s10434-019-07638-8Test
https://www.malignanttumors.org/jour/article/view/1273Test

View record in BASE

6

دورية أكاديمية

Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.

المؤلفون: Lauritsen, J, Sauvé, N, Tryakin, A, Jiang, DM, Huddart, R, Heng, DYC, Terbuch, A, Winquist, E, Chovanec, M, Hentrich, M, Fankhauser, CD, Shamash, J, Del Muro, XG, Vaughn, D, Heidenreich, A, Sternberg, CN, Sweeney, C, Necchi, A, Bokemeyer, C, Bandak, M, Jandari, A, Collette, L, Gillessen, S, Beyer, J, Daugaard, G

المساهمون: Huddart, Robert

مصطلحات موضوعية: Male, Humans, Testicular Neoplasms, Prognosis, Neoplasms, Germ Cell and Embryonal, Progression-Free Survival, Seminoma, Second Primary, Recurrence

جغرافية الموضوع: England

وصف الملف: Print-Electronic; 1765; application/pdf

العلاقة: British Journal of Cancer, 2023, 129 (11), pp. 1759 - 1765; https://repository.icr.ac.uk/handle/internal/6205Test

الإتاحة: https://doi.org/10.1038/s41416-023-02443-3Test
https://repository.icr.ac.uk/handle/internal/6205Test

View record in BASE

النص الكامل

7

دورية أكاديمية

Changes in clinical guidelines for the treatment of colorectal cancer in 2024 ; Изменения в клинических рекомендациях по лечению колоректального рака в 2024 году

المؤلفون: S. S. Gordeev, M. Yu. Fedyanin, M. V. Chernykh, Ye. G. Rubakov, A. M. Karachun, A. A. Nevolskikh, A. A. Tryakin, Z. Z. Mamedli, С. С. Гордеев, М. Ю. Федянин, М. В. Черных, Е. Г. Рыбаков, А. М. Карачун, А. А. Невольских, А. А. Трякин, З. З. Мамедли

المصدر: Surgery and Oncology; Том 14, № 1 (2024); 21-31 ; Хирургия и онкология; Том 14, № 1 (2024); 21-31 ; 2949-5857

مصطلحات موضوعية: тотальная неоадъювантная терапия, colon cancer, colorectal cancer, clinical guidelines, neoadjuvant chemotherapy, total neoadjuvant therapy, рак ободочной кишки, колоректальный рак, клинические рекомендации, неоадъювантная химиотерапия

وصف الملف: application/pdf

العلاقة: https://www.onco-surgery.info/jour/article/view/687/451Test; Sakamoto T., Shimura M., Kitano S. et al. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007;243(1):132–9. DOI:10.1148/radiol.2431051825; Engstrom P.F., Arnoletti J.P., Benson A.B. 3rd et al. Rectal cancer. J Natl Compr Canc Netw 2009:7(8):838–81. DOI:10.6004/jnccn.2009.0057; De Caluwé L., Van Nieuwenhove Y., Ceelen W.P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2013(2):CD006041. DOI:10.1002/14651858.CD006041.pub3; Bahadoer R.R., Dijkstra E.A., van Etten B. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22(1):29–42. DOI:10.1016/S1470-2045(20)30555-6; Dijkstra E.A., Nilsson P.J., Hospers G.A.P. et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery–a five-year follow-up of the RAPIDO trial. Ann Surg 2023;278(4):e766–72. DOI:10.1097/SLA.0000000000005799; Song J.H., Jeong J.U., Lee J.H. et al. Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for stage II–III resectable rectal cancer: a meta-analysis of randomized controlled trials. Radiat Oncol J 2017;35(3): 198–207. DOI:10.3857/roj.2017.00059; Battersby N.J., How P., Moran B. et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study. Ann Surg 2016;263(4):751–60. DOI:10.1097/SLA.0000000000001193; Marinello F.G., Frasson M., Baguena G. et al. Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary. Dis Colon Rectum 2015;58(6):556–65. DOI:10.1097/DCR.0000000000000349; Rosenberg R., Maak M., Schuster T. et al. Does a rectal cancer of the upper third behave more like a colon or a rectal cancer? Dis Colon Rectum 2010;53(5):761–70. DOI:10.1007/DCR.0b013e3181cdb25a; Folkesson J., Birgisson H., Pahlman L. et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005;23(24):5644–50. DOI:10.1200/JCO.2005.08.144; Sebag-Montefiore D., Stephens R.J., Steele R. et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373(9666):811–20. DOI:10.1016/S0140-6736(09)60484-0; Van Gijn W., Marijnen C.A., Nagtegaal I.D. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12(6):575–82. DOI:10.1016/S1470-2045(11)70097-3; Morton D., Seymour M., Magill L. et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol 2023;41(8):1541. DOI:10.1200/JCO.22.00046; Hu H., Huang M., Li Y. et al. Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial. J Clin Oncol 2022;40(16_suppl). DOI:10.1200/JCO.2022.40.16_suppl.3500; Jensen L.H., Kjaer M.L., Holländer N.H., Larsen F.O. Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. J Clin Oncol 2023;41(17_suppl):LBA3503. DOI:10.1200/JCO.2023.41.17_suppl.LBA3503; Karoui M., Rullier A., Piessen G. et al. Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase II multicenter randomized controlled trial (PRODIGE 22). Ann Surg 2020;271(4):637–45. DOI:10.1097/SLA.0000000000003454; Ngan S.Y., Burmeister B., Fisher R.J. et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012;30(31):3827–33. DOI:10.1200/JCO.2012.42.9597; Cisel B., Pietrzak L., Michalski W. et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol 2019;30(8):1298–303. DOI:10.1093/annonc/mdz186; Dijkstra E.A., Hospers G.A.P., Kranenbarg E.M. et al. Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer – The RAPIDO trial. Radiother Oncol 2022;171:69–76. DOI:10.1016/j.radonc.2022.04.013; Birgisson H., Påhlman L., Gunnarsson U., Glimelius B. Late adverse effects of radiation therapy for rectal cancer – a systematic overview. Acta Oncol 2007;46(4):504–16. DOI:10.1080/02841860701348670; Grothey A., Sobrero A.F., Shields A.F. et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018;378(13):1177–88. DOI:10.1056/NEJMoa1713709; Schrag D. PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC)(Alliance N1048). American Society of Clinical Oncology 2023.; Mei W.-J., Wang X.Z., Li Y.F. et al. Neoadjuvant chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): initial results of a phase III trial. Ann Surg 2023;277(4):557–64. DOI:10.1097/SLA.0000000000005780; Hazen S.-M.J., Sluckin T.C., Intven M.P.W. et al. Abandonment of Routine Radiotherapy for Nonlocally Advanced Rectal Cancer and Oncological Outcomes. JAMA Oncol 2024;10(2):202–11. DOI:10.1001/jamaoncol.2023.5444; Sychev S., Ponomarenko A., Chernyshov S. et al. Total neoadjuvant therapy in rectal cancer: a network meta-analysis of randomized trials. Ann Coloproctol 2023;39(4):289–300. DOI:10.3393/ac.2022.00920.0131; Verheij F.S., Omer D.M., Williams H. et al. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J Clin Oncol 2023:42(5):500–6. DOI:10.1200/JCO.23.01208; Liao C.-K., Kuo Y.T., Lin Y.C. et al. Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer: a systematic review and meta-analysis. Curr Oncol 2022;29(5):3708–27. DOI:10.3390/curroncol29050297; Verheij F.S., Omer D.M.R., Williams H. et al. Sustained organ preservation in patients with rectal cancer treated with total neoadjuvant therapy: Long-term results of the OPRA trial. J Clin Oncol 2023;41(16_suppl). DOI:10.1200/JCO.2023.41.16_suppl.352; Romesser P.B., Park B.K., Nemirovsky D. et al. Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy. J Clin Oncol 2023;41(4_suppl). DOI:10.1200/JCO.2023.41.4_suppl.10; Van der Valk M.J., Hilling D.E., Bastiaannet E. et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 2018;391(10139):2537–45. DOI:10.1016/S0140-6736(18)31078-X; Ellis C.T., Cole A.L., Sanoff H.K. et al. Evaluating surveillance patterns after Chemoradiation-only compared with conventional Management for Older Patients with rectal cancer. J Am Coll Surg 2019;228(5):782–91. DOI:10.1016/j.jamcollsurg.2019.01.010; Giordano P., Efron J., Vernava A.M. 3rd et al. Strategies of followup for colorectal cancer: a survey of the American Society of Colon and Rectal Surgeons. Tech Coloproctol 2006;10(3):199–207. DOI:10.1007/s10151-006-0280-3; Федянин М., Гладков О., Гордеев С. и др. Рак ободочной кишки, ректосигмоидного соединения и прямой кишки. Злокачественные опухоли 2023;13(3s2-1):425–82. DOI:10.18027/2224-5057-2023-13-3s2-1-425-482; Федянин М., Трякин А.А., Буланов А.А. и др. К вопросу о числе лимфатических узлов, необходимых к изучению при раке толстой кишки II стадии. Тазовая хирургия и онкология 2019;9(1):42–50. DOI:10.17650/2220-3478-2019-9-1-42-50; Jeon J., Shen L., Kim Y. et al. The number of lymph nodes examined as a poor prognosis factor in stage II and stage III colon cancer patients undergoing curative surgery. J Clin Oncol 2023;41(16_suppl). DOI:10.1200/JCO.2023.41.16_suppl.3612; Ahmed F., Selfridge J., Kakishet H. et al. SO-19 The outcome of resected stage II colon cancer patients with deficient mismatch repair T4 tumors: A National Cancer Database analysis. Ann Oncol 2023;34(1_suppl):S170. DOI:10.1016/j.annonc.2023.04.491; Fleming P., Chen Ch., Moore D.F. et al. High-risk MSI-H stage II colon cancer: Treatment patterns and outcomes. J Clin Oncol 2022;40(16_suppl). DOI:10.1200/JCO.2022.40.16_suppl.e15588; Oki E., Kotani D., Nakamura Y. et al. Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan. J Clin Oncol 2023;41(16_suppl). DOI:10.1200/JCO.2023.41.16_suppl.3521; Tie J., Cohen J.D., Lahouel K. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 2022;386(24):2261–72. DOI:10.1056/NEJMoa2200075; Cohen S.A., Kasi P.M., Aushev V.N., Hanna D. Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I–III colorectal cancer. J Clin Oncol 2023;41(4_suppl):5. DOI:10.1200/JCO.2023.41.4_suppl.5; Karoui M., Gallois C., Piessen G. et al. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years’ follow-up results of the PRODIGE 22 phase II randomized multicentre trial. Colorectal Dis 2021;23(6):1357–69. DOI:10.1111/codi.15585; https://www.onco-surgery.info/jour/article/view/687Test

الإتاحة: https://doi.org/10.17650/2949-5857-2024-14-1-21-31Test
https://doi.org/10.1148/radiol.2431051825Test
https://doi.org/10.6004/jnccn.2009.0057Test
https://doi.org/10.1002/14651858.CD006041.pub3Test
https://doi.org/10.1016/S1470-2045Test(20)30555-6
https://doi.org/10.1097/SLA.0000000000005799Test
https://doi.org/10.3857/roj.2017.00059Test
https://doi.org/10.1097/SLA.0000000000001193Test
https://doi.org/10.1097/DCR.0000000000000349Test
https://doi.org/10.1200/JCO.2005.08.144Test